Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.e

Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

Publications

Raschi E, Antonazzo IC, Poluzzi E, De Ponti F

Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?

Annals of the rheumatic diseases 2019 Jun 12;; — 2019 Jun 12

de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

Cancer immunology research 2019 01;7;6-11 — 2019 01 — 6-11

Tocut M, Brenner R, Zandman-Goddard G

Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors.

Autoimmunity reviews 2018 Jun;17;610-616 — 2018 Jun — 610-616

Kong YC, Wei WZ, Tomer Y

Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.

Annals of the New York Academy of Sciences 2010 Jan;1183;222-36 — 2010 Jan — 222-36